NASDAQ:VKTX - Viking Therapeutics Stock Price, Forecast & News

Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."

Viking Therapeutics Inc (NASDAQ:VKTX) posted its earnings results on Tuesday, November, 5th. The biotechnology company reported ($0.08) EPS for the quarter, topping the Zacks' consensus estimate of ($0.13) by $0.05. View Viking Therapeutics' Earnings History.

Viking Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Viking Therapeutics.

Viking Therapeutics will be holding an earnings conference call on Wednesday, February 26th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

11 equities research analysts have issued 12-month price objectives for Viking Therapeutics' stock. Their forecasts range from $8.86 to $40.00. On average, they expect Viking Therapeutics' stock price to reach $18.76 in the next year. This suggests a possible upside of 170.7% from the stock's current price. View Analyst Price Targets for Viking Therapeutics.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last year. There are currently 10 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Viking Therapeutics.

News headlines about VKTX stock have trended very negative this week, InfoTrie reports. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Viking Therapeutics earned a coverage optimism score of -3.0 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Viking Therapeutics.

Viking Therapeutics saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 16,420,000 shares, an increase of 10.2% from the January 15th total of 14,900,000 shares. Based on an average daily volume of 1,346,900 shares, the short-interest ratio is currently 12.2 days. Approximately 25.6% of the company's shares are short sold. View Viking Therapeutics' Current Options Chain.

Some companies that are related to Viking Therapeutics include Eidos Therapeutics (EIDX), Heron Therapeutics (HRTX), IGM Biosciences (IGMS), Ironwood Pharmaceuticals (IRWD), Zymeworks (ZYME), Tricida (TCDA), Ligand Pharmaceuticals (LGND), Akcea Therapeutics (AKCA), Arvinas (ARVN), BELLUS Health (BLUSF), Esperion Therapeutics (ESPR), Aimmune Therapeutics (AIMT), Alder Biopharmaceuticals (ALDR), TG Therapeutics (TGTX) and Corcept Therapeutics (CORT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Viking Therapeutics investors own include NVIDIA (NVDA), Verastem (VSTM), Amarin (AMRN), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Novavax (NVAX), TG Therapeutics (TGTX), AT&T (T) and Advanced Micro Devices (AMD).

(VKTX) raised $20 million in an IPO on Wednesday, April 29th 2015. The company issued 2,500,000 shares at $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO and Feltl and Company was co-manager.

Viking Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include ArrowMark Colorado Holdings LLC (12.20%), State Street Corp (5.00%), FMR LLC (3.03%), Fiera Capital Corp (1.66%), Geode Capital Management LLC (1.26%) and UBS Group AG (0.57%). Company insiders that own Viking Therapeutics stock include J Matthew Singleton, Lawson Macartney, Ligand Pharmaceuticals Inc and Michael Morneau. View Institutional Ownership Trends for Viking Therapeutics.

VKTX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, State Street Corp, SG Americas Securities LLC, UBS Group AG, Rafferty Asset Management LLC, Fiera Capital Corp, Raymond James & Associates and Blair William & Co. IL. View Insider Buying and Selling for Viking Therapeutics.

VKTX stock was bought by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, Geode Capital Management LLC, Credit Suisse AG, California Public Employees Retirement System, Goldman Sachs Group Inc., Barclays PLC, Blueshift Asset Management LLC and Bank of New York Mellon Corp. Company insiders that have bought Viking Therapeutics stock in the last two years include J Matthew Singleton and Lawson Macartney. View Insider Buying and Selling for Viking Therapeutics.

Shares of VKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of VKTX stock can currently be purchased for approximately $6.93.

Viking Therapeutics has a market capitalization of $500.76 million. The biotechnology company earns $-22,060,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. Viking Therapeutics employs 15 workers across the globe.View Additional Information About Viking Therapeutics.

The official website for Viking Therapeutics is http://www.vikingtherapeutics.com/.

Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-704-4660 or via email at [email protected]